John Valliant
2019
In 2019, John Valliant earned a total compensation of $1.4M as Chief Executive Officer at Fusion Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $136,927 |
|---|---|
| Option Awards | $835,095 |
| Salary | $399,299 |
| Other | $28,233 |
| Total | $1,399,554 |
Valliant received $835.1K in option awards, accounting for 60% of the total pay in 2019.
Valliant also received $136.9K in non-equity incentive plan, $399.3K in salary and $28.2K in other compensation.
Rankings
In 2019, John Valliant's compensation ranked 7,675th out of 13,971 executives tracked by ExecPay. In other words, Valliant earned more than 45.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,675 out of 13,971 | 45th |
Division Manufacturing | 2,991 out of 5,695 | 48th |
Major group Chemicals And Allied Products | 1,123 out of 2,194 | 49th |
Industry group Drugs | 957 out of 1,880 | 49th |
Industry Biological Products, Except Diagnostic Substances | 221 out of 389 | 43rd |
Source: SEC filing on April 27, 2021.
Valliant's colleagues
We found two more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2019.